Want to see AXGN full AI Analyst Report?
AXGN Stock Chart & Stats
$38.50
>-$0.01(>-0.01%)
At close: 4:00 PM EST
$38.50
>-$0.01(>-0.01%)
Day’s Range― - ―
52-Week Range$11.25 - $46.95
Previous CloseN/A
Volume66.42K
Average Volume (3M)801.93K
Market Cap
$2.32B
Enterprise Value$2.31B
Total Cash (Recent Filing)$82.65M
Total Debt (Recent Filing)$20.64M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 12, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding53,177,822
10 Day Avg. Volume462,742
30 Day Avg. Volume801,935
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue9.69
Enterprise Value/Gross Profit12.92
Enterprise Value/Ebitda-280.15
Forecast
1Y Price Target
$50.13Price Target Upside30.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.5
Revenue Forecast (FY)$270.88M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 74–75% indicate durable product-level profitability from Avance and adjunct products. High margins provide room for scaling the commercial organization, absorb price pressure, and support operating leverage as revenue grows toward sustained profitability.
Improving Cash GenerationThe shift to positive operating and free cash flow, plus a strengthened cash balance after an equity raise, materially lowers near-term liquidity risk. This provides runway to invest in sales and processing capacity, reduces refinancing pressure, and supports execution on commercial expansion.
Favorable Reimbursement ChangesA new CMS procedure code and positive commercial insurer decisions are structural demand drivers that improve economics for surgeons and hospitals. Better reimbursement reduces adoption friction, supports procedure volume growth, and helps sustain uptake of Avance and adjunct products over the medium term.
Bears Say
Persistent Net LossesOngoing net losses mean returns remain negative and internal capital generation is limited. The company must convert margin and cash-flow improvements into durable GAAP profitability to avoid repeated dilution or reliance on capital markets to fund growth and operations over the medium term.
Slower TTM Revenue GrowthTTM revenue growth slowing to mid-single digits indicates that earlier rapid adoption may be tempering. Management's ability to sustainably re-accelerate revenue (guidance targets ~20%) depends on execution across markets, making future margin expansion and profitability more uncertain if growth does not re-accelerate.
Cash Flow Volatility / Funding SensitivityAlthough cash flows are positive TTM, prior steep declines and volatility create planning uncertainty. The company used an equity offering to repay debt, highlighting funding sensitivity; inconsistent cash conversion complicates long-term investments and raises the bar for self-funded expansion.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $11.25 and its highest was $46.95 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $2.32B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Apr 28, 2026. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.075 by -$0.005.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.12.
How many shares outstanding does AxoGen have?
AxoGen has 53,177,822 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.07 in its last earnings report, missing expectations of $0.075. Following the earnings report the stock price went up 6.601%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.13 (30.19% Upside)
$50.13 (30.19% Upside)
Hedge Fund Trend
Increased
By 24.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.02%
12-Months-Change
Fundamentals
Return on Equity
-20.74%
Trailing 12-Months
Asset Growth
47.57%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
AXGN Company Deck
AXGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents materially positive operational and strategic progress: robust revenue growth (Q4 +21.3% YoY; FY +20.2% YoY), a strong capital raise and debt retirement, positive adjusted EBITDA and cash flow for the year, and a transformative FDA BLA approval that establishes Avance as the reference biologic. Near-term challenges include one-time BLA-related noncash charges, elevated operating expenses (notably R&D and G&A), a Q4 net loss and short-term gross margin pressure as the product mix shifts to the biologic. Management provided prudent guidance (≥18% revenue growth for 2026) and expects margin recovery in 2027 as scale and process improvements are implemented. Overall, the highlights outweigh the lowlights given the regulatory milestone, healthy top-line growth, improved adjusted EBITDA and strengthened balance sheet, supporting a constructive outlook despite short-term cost pressure.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$50.13
▲(30.19% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.61% Insiders
20.25% Mutual Funds
4.52% Other Institutional Investors
58.95% Public Companies and
Individual Investors








